FindTrial
Sign In

Jakavi 20 mg tablets

DRUG7 trials

Sponsors

Karyopharm Therapeutics Inc., Takeda Development Center Americas Inc., Ryvu Therapeutics S.A., Novartis Pharma Services AG, Universitaetsklinikum Aachen AöR

Conditions

MyelofibrosisPatients with relapsed or refractory cHL that has not responded toThis study is designed to accept patients with varied disease originsTreatment naïve patients with MFdepending on the parent protocolessential thrombocythemiahaemophagocytic lymphohistiocytosis (HLH) in childrenor has progressed after

Phase 2

Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trial
Active, not recruitingCTIS2024-515619-23-00
Universitaetsklinikum Aachen AöRessential thrombocythemia, polycythemia vera
Start: 2015-06-29Target: 223Updated: 2025-09-01
An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
RecruitingCTIS2024-511688-27-00
Ryvu Therapeutics S.A.Myelofibrosis
Start: 2024-09-19Target: 83Updated: 2025-12-16
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis.
Active, not recruitingCTIS2023-507468-38-00
Takeda Development Center Americas Inc.Myelofibrosis
Start: 2022-04-22Target: 47Updated: 2025-12-16
R-HLH - Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study
RecruitingCTIS2024-516105-23-01
Assistance Publique Hopitaux De Parishaemophagocytic lymphohistiocytosis (HLH) in children
Start: 2024-11-10Target: 20Updated: 2024-12-16
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
RecruitingCTIS2024-520123-83-01
Universita' Degli Studi Di Perugiaor has progressed after, Patients with relapsed or refractory cHL that has not responded to, the previous treatment. Neither Cohort-1 nor Cohort-2 are open to patients with a partial response after the immediate prior treatment (including salvage therapy before autologous or allogeneic transplantation); such patients would become eligible only upon subsequent progression.
Start: 2020-02-11Target: 48Updated: 2026-01-23

Phase 3

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
Active, not recruitingCTIS2023-506139-13-00
Karyopharm Therapeutics Inc.Treatment naïve patients with MF
Start: 2024-01-04Target: 195Updated: 2025-10-09

Phase 4

An open label, multi-center, Phase IV rollover protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with either panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462), and are judged by the investigator to benefit from continued treatment
Active, not recruitingCTIS2024-515283-31-00
Novartis Pharma Services AGdepending on the parent protocol, This study is designed to accept patients with varied disease origins
Start: 2015-07-30Target: 33Updated: 2025-12-09